The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 06, 2025
Filed:
Sep. 03, 2019
Applicant:
Bioinvent International Ab, Lund, SE;
Inventors:
Björn Frendéus, Lund, SE;
Ingrid Teige, Lund, SE;
Monika Semmrich, Malmö, SE;
Linda Mårtensson, Bjärred, SE;
Petra Holmkvist, Kävlinge, SE;
Assignee:
BIOINVENT INTERNATIONAL AB, Lund, SE;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2005.12); A61P 35/00 (2005.12); C12N 7/00 (2005.12); C12N 15/86 (2005.12); A61K 39/00 (2005.12);
U.S. Cl.
CPC ...
C07K 16/2818 (2012.12); A61P 35/00 (2017.12); C12N 7/00 (2012.12); C12N 15/86 (2012.12); A61K 2039/505 (2012.12); C07K 2317/33 (2012.12); C07K 2317/565 (2012.12); C07K 2317/732 (2012.12); C07K 2317/76 (2012.12); C12N 2710/24143 (2012.12);
Abstract
Described are novel anti-CTLA-4 antibody molecules and nucleotide sequences and expression vectors, such as viruses, encoding such antibody molecules. The novel antibody molecules are Treg depleting antibody molecules, and they have an improved depleting effect on CTLA-4 positive cells, such as Tregs, compared to ipilimumab. Described is also the use of such antibody molecules or nucleotide sequences or viruses in medicine, such as in the treatment of cancer, such as solid tumours.